<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777412</url>
  </required_header>
  <id_info>
    <org_study_id>Avastin_NMO_1</org_study_id>
    <nct_id>NCT01777412</nct_id>
  </id_info>
  <brief_title>Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations</brief_title>
  <official_title>An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guthy Jackson Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the
      tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for
      treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO)
      and neuromyelitis optica spectrum disorder (NMOSD). A single infusion of Avastin® is added to
      standard-of-care high dose steroids and an additional dose of Avastin® is added to plasma
      exchange (if necessary). The primary outcomes are clinical changes in the Expanded Disability
      Severity Scale, Timed 25-foot Walk and Low Contrast Visual Acuity, MRI parameters and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective: The overall objective is to evaluate the tolerability/safety and efficacy of
      adding bevacizumab (Avastin®) to standard of care therapy in improving clinical and
      radiologic outcomes of acute optic neuritis and/or transverse myelitis in neuromyelitis
      optica and neuromyelitis optica spectrum disorders.

      Primary Objective: To compare the clinical and radiographic outcome following acute optic
      neuritis and/or transverse myelitis in NMO/NMOSD in patients who receive 1-2 doses of 10
      mg/kg dose of bevacizumab (Avastin®) in addition to standard medical therapy.

      Secondary Objectives:

        -  To determine the effect of Avastin on NMO clinical scores (Expanded Disability Status
           Scale, Timed 25-foot Walk and Low Contrast Visual Acuity [LCVA]).

        -  To evaluate the safety and tolerability of a 10 mg/kg dose of intravenous Avastin.

        -  To determine the frequency of adverse events with Avastin in this patient population.

        -  To determine the effect of Avastin on MRI lesion size and extent.

      The duration of the investigation is 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Expanded Disability Status Score (EDSS)</measure>
    <time_frame>Admission to hospital</time_frame>
    <description>EDSS
The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Assessment and Side Effects</measure>
    <time_frame>91 days</time_frame>
    <description>Frequency and severity of adverse events and side effects. Serious adverse events are considered those which are life threatening, lead to hospitalization and related to the drug. Side effects are considered minor effects of the experimental drug that do not significantly impact the care of the patient with the experimental drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-Up Expanded Disability Status Score (EDSS)</measure>
    <time_frame>Follow-up visit 91 days after admission</time_frame>
    <description>EDSS
The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects eligible for enrollment must meet all of the following criteria:

          1. Able and willing to provide written informed consent.

          2. 18-70 years of age.

          3. New acute optic neuritis and/or transverse myelitis. A clinical event is defined as an
             episode of inflammation in the spinal cord and/or optic nerve leading to neurologic
             symptoms not ascribed to another disease process.

          4. Known or suspected diagnosis of NMO according to the 2006 revisions of the Wingerchuk
             diagnostic criteria for NMO or AQP4 positive NMOSD per the EFNS Guidelines. For NMO,
             subjects must have two absolute criteria:

               1. optic neuritis

               2. myelitis and at least two of three supportive criteria:

               3. presence of a contiguous spinal cord MRI lesion extending over three or more
                  vertebral segments,

               4. MRI criteria NOT satisfying the revised McDonald diagnostic criteria for MS
                  [Polman, 2011]

               5. NMO-IgG (AQP4) in serum. For NMOSD, subjects must have longitudinally extensive
                  transverse myelitis (LETM) recurrent isolated optic neuritis (RION)/bilateral
                  optic neuritis (BON), or opticospinal multiple sclerosis (OSMS) that is AQP4
                  antibody positive

          5. A female subject is eligible to enter the study if she is:

        A. Not pregnant or nursing; B. Of non-childbearing potential (i.e. women who have had a
        hysterectomy, are postmenopausal, which is defined as &gt;2 years without menses (female
        subjects who have been post-menopausal for &lt;2 years must be confirmed with Follicle
        Stimulating Hormone (FSH) and estradiol levels), have both ovaries surgically removed or
        have current documented tubal ligation); or,

        C. Of childbearing potential (i.e. women with functional ovaries and no documented
        impairment of oviductal or uterine function that would cause sterility). This category
        includes women with oligomenorrhoea (even severe), women who are perimenopausal or have
        just begun to menstruate. The subject must have a negative serum pregnancy test at
        screening and agrees to one of the following:

        i. Complete abstinence from intercourse for the period from consent into the study until 6
        months after the last dose of investigational product; or, ii. Consistent and correct use
        of one of the following acceptable methods of birth control for the period from consent
        into the study until 6 months after the last dose of investigational product:

          1. Oral contraceptives (either combined or progesterone only)

          2. Injectable progesterone

          3. Levonorgestrel implants

          4. Estrogenic vaginal ring

          5. Percutaneous contraceptive patches

          6. Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate
             of &lt;1% per year

          7. Male partner sterilization (vasectomy with documentation of azoospermia) prior to the
             female subject's entry into the study; this male must be the sole partner for the
             subject

          8. Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps)
             with a vaginal spermicidal agent (foam/gel/film/cream/suppository).

        Subjects meeting any of the following criteria are not eligible and cannot enroll in the
        study:

          1. Evidence or history of clinically significant infection including:

               1. Chronic or ongoing active infectious disease requiring long term systemic
                  treatment such as, but not limited to: PML, chronic renal infection, chronic
                  chest infection with bronchiectasis, tuberculosis, or active hepatitis C.

               2. Positive test for HBsAg.

               3. Prior history, or suspicion, of tuberculosis (TB)

               4. History of positive serology for HIV.

          2. Past or current malignancy, except for

               1. Cervical carcinoma Stage 1B or less

               2. Non-invasive basal cell and squamous cell skin carcinoma

               3. Cancer diagnoses with a duration of complete response (remission) &gt;5 years

               4. A history of hematologic malignancy excludes a subject from participation,
                  regardless of response.

          3. Recent major surgery within the last 28 days.

          4. Significant concurrent, uncontrolled medical condition including, but not limited to,
             cardiac, renal, hepatic, hematological, gastrointestinal, endocrine, immunodeficiency
             syndrome, pulmonary, cerebral, psychiatric, or neurological disease which could affect
             the subject's safety, impair the subject's reliable participation in the trial, impair
             the evaluation of endpoints, or necessitate the use of medication not allowed by the
             protocol.

          5. Use of an investigational drug or other experimental therapy for a condition other
             than NMO within 4 weeks, 5 pharmacokinetic half lives or duration of biological effect
             (whichever is longer) prior to screening.

          6. Current participation in any other interventional clinical trial. Participation in
             non-interventional trial requires approval of the protocol by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Levy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.guthyjacksonfoundation.org/</url>
    <description>Guthy Jackson Charitable Foundation</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <results_first_submitted>May 13, 2015</results_first_submitted>
  <results_first_submitted_qc>May 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2015</results_first_posted>
  <last_update_submitted>August 1, 2015</last_update_submitted>
  <last_update_submitted_qc>August 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Michael Levy</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>NMO</keyword>
  <keyword>NMOSD</keyword>
  <keyword>NMO-IgG</keyword>
  <keyword>Aquaporin-4</keyword>
  <keyword>AQP4</keyword>
  <keyword>anti-AQP4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab</title>
          <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase in additional 5 days of 1000 mg methylprednisolone infusion. There was no placebo or comparator group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab</title>
          <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase in additional 5 days of 1000 mg methylprednisolone infusion. There was no placebo or comparator group.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NMO/NMOSD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High risk for NMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-AQP4 antibody serostatus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Expanded Disability Status Score (EDSS)</title>
        <description>EDSS
The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.</description>
        <time_frame>Admission to hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase in additional 5 days of 1000 mg methylprednisolone infusion. There was no placebo or comparator group.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Expanded Disability Status Score (EDSS)</title>
          <description>EDSS
The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Assessment and Side Effects</title>
        <description>Frequency and severity of adverse events and side effects. Serious adverse events are considered those which are life threatening, lead to hospitalization and related to the drug. Side effects are considered minor effects of the experimental drug that do not significantly impact the care of the patient with the experimental drug.</description>
        <time_frame>91 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase in additional 5 days of 1000 mg methylprednisolone infusion. There was no placebo or comparator group.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment and Side Effects</title>
          <description>Frequency and severity of adverse events and side effects. Serious adverse events are considered those which are life threatening, lead to hospitalization and related to the drug. Side effects are considered minor effects of the experimental drug that do not significantly impact the care of the patient with the experimental drug.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Event: Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Follow-Up Expanded Disability Status Score (EDSS)</title>
        <description>EDSS
The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.</description>
        <time_frame>Follow-up visit 91 days after admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase in additional 5 days of 1000 mg methylprednisolone infusion. There was no placebo or comparator group.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-Up Expanded Disability Status Score (EDSS)</title>
          <description>EDSS
The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.75" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>91 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab</title>
          <description>Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase in additional 5 days of 1000 mg methylprednisolone infusion. There was no placebo or comparator group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Urinary Tract Infection</sub_title>
                <description>47 days after infusion of bevacizumab, patient developed a urinary tract infection that required hospitalization for 1 night and initiation of antibiotics. The infection was treated completely without complications.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache during the infusion of bevacizumab was noted. The headache resolved with fluids.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Levy</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>443-287-4412</phone>
      <email>mlevy@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

